Xylazine is a widely used veterinary sedative and analgesic drug. However, due to the manufacturing process, it may contain impurities, which can affect its safety and efficacy. These impurities can be formed during synthesis or storage and can be toxic or carcinogenic, leading to adverse effects in animals and humans. Therefore, it is important to monitor and control the levels of Xylazine impurities to ensure the safety and quality of the drug.